{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:08Z","timestamp":1791908408686,"version":"4.3.4"},"reference-count":31,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15299","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:50:07Z","timestamp":1758801007000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2011world investigation for camrelizumab combined with apatinib in patients with advanced hepatocellular carcinoma"],"prefix":"10.3892","volume":"30","author":[{"given":"Liyang","family":"Yin","sequence":"first","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijia","family":"An","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Emergency Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Handan Central Hospital, Handan, Hebei 056000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"key20251111103816_b1-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"key20251111103816_b2-ol-30-6-15299","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20251111103816_b3-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"key20251111103816_b4-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"Galle","year":"2021","journal-title":"Future Oncol"},{"key":"key20251111103816_b5-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20251111103816_b6-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"749083","DOI":"10.3389\/fonc.2021.749083","article-title":"Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: A review","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"key20251111103816_b7-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"944062","DOI":"10.3389\/fimmu.2022.944062","article-title":"Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"key20251111103816_b8-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"961394","DOI":"10.3389\/fonc.2022.961394","article-title":"Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study","volume":"12","author":"Xia","year":"2022","journal-title":"Front Oncol"},{"key":"key20251111103816_b9-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/22123970MTE0eMDY90","article-title":"Current status and prospects of camrelizumab, A humanized antibody against programmed cell death receptor 1","volume":"16","author":"Song","year":"2021","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"key20251111103816_b10-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20251111103816_b11-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20251111103816_b12-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): A randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"key20251111103816_b13-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejrad.2018.01.025","article-title":"Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines","volume":"101","author":"Ayuso","year":"2018","journal-title":"Eur J Radiol"},{"key":"key20251111103816_b14-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1-standardisation and disease-specific adaptations: Perspectives from the RECIST working group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20251111103816_b15-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"17562848241237631","DOI":"10.1177\/17562848241237631","article-title":"The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: A systematic review and network meta-analysis","volume":"17","author":"Peng","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"key20251111103816_b16-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"e008942","DOI":"10.1136\/jitc-2024-008942","article-title":"Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: Post-hoc analysis of a single center, phase 2 study","volume":"12","author":"Feng","year":"2024","journal-title":"J Immunother Cancer"},{"key":"key20251111103816_b17-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"2503645","DOI":"10.1080\/07853890.2025.2503645","article-title":"Discovery of novel diagnostic biomarkers of hepatocellular carcinoma associated with immune infiltration","volume":"57","author":"Liu","year":"2025","journal-title":"Ann Med"},{"key":"key20251111103816_b18-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"key20251111103816_b19-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/jcm9030675","article-title":"Combining immune checkpoint inhibitors with anti-angiogenic agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J Clin Med"},{"key":"key20251111103816_b20-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"835889","DOI":"10.3389\/fonc.2021.835889","article-title":"Apatinib plus camrelizumab with\/without chemoembolization for hepatocellular carcinoma: A real-world experience of a single center","volume":"11","author":"Ju","year":"2022","journal-title":"Front Oncol"},{"key":"key20251111103816_b21-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"key20251111103816_b22-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00262-023-03404-8","article-title":"Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"key20251111103816_b23-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"12683","DOI":"10.2147\/OTT.S286169","article-title":"Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: A multicenter retrospective study","volume":"13","author":"Yuan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"key20251111103816_b24-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"e002191","DOI":"10.1136\/jitc-2020-002191","article-title":"Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: Cohort A report in a multicenter phase Ib\/II trial","volume":"9","author":"Mei","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20251111103816_b25-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4149\/neo_2023_230413N206","article-title":"Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: A real-world assessment","volume":"70","author":"Chen","year":"2023","journal-title":"Neoplasma"},{"key":"key20251111103816_b26-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jvir.2018.03.027","article-title":"Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: Results of a single-center double-blind prospective randomized controlled trial","volume":"29","author":"He","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"key20251111103816_b27-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20251111103816_b28-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.21037\/atm-20-2990","article-title":"Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: A phase II clinical trial","volume":"8","author":"Hou","year":"2020","journal-title":"Ann Transl Med"},{"key":"key20251111103816_b29-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): A propensity score matching study","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"key20251111103816_b30-ol-30-6-15299","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.hbpd.2024.10.003","article-title":"Sequential living donor liver transplantation after liver resection optimizes outcomes for patients with high-risk hepatocellular carcinoma","volume":"24","author":"Chen","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key20251111103816_b31-ol-30-6-15299","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2025.05.004","article-title":"Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma","author":"Zhu","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:38:21Z","timestamp":1762850301000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15299","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}